Published in Cell Discov on July 04, 2017
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab (2008) 18.87
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
Metformin and reduced risk of cancer in diabetic patients. BMJ (2005) 13.04
Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol (2003) 12.91
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J (2004) 10.82
miR-21-mediated tumor growth. Oncogene (2006) 9.90
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet (2005) 7.15
p53 target genes sestrin1 and sestrin2 connect genotoxic stress and mTOR signaling. Cell (2008) 6.88
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature (2010) 5.73
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med (2012) 5.46
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
MO25alpha/beta interact with STRADalpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J (2003) 3.77
The retinoblastoma protein binds to a family of E2F transcription factors. Mol Cell Biol (1993) 3.75
Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther (2010) 2.93
Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science (2009) 2.13
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol (2010) 2.11
Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem (2010) 2.03
The regulation of AMP-activated protein kinase by upstream kinases. Int J Obes (Lond) (2008) 1.98
Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev (2004) 1.97
The blooming of the French lilac. J Clin Invest (2001) 1.80
An Ancient, Unified Mechanism for Metformin Growth Inhibition in C. elegans and Cancer. Cell (2016) 1.49
Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. Diabetologia (2011) 1.48
Metformin elicits anticancer effects through the sequential modulation of DICER and c-MYC. Nat Commun (2012) 1.41
mTOR signaling for biological control and cancer. J Cell Physiol (2013) 1.40
miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis (2012) 1.33
Biguanides. Diabetologia (1978) 1.24
Metformin and cancer: from the old medicine cabinet to pharmacological pitfalls and prospects. Trends Pharmacol Sci (2012) 1.14
Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol (2011) 1.08
Defining the contribution of AMP-activated protein kinase (AMPK) and protein kinase C (PKC) in regulation of glucose uptake by metformin in skeletal muscle cells. J Biol Chem (2012) 1.03
The chromatin remodeller CHD8 is required for E2F-dependent transcription activation of S-phase genes. Nucleic Acids Res (2013) 1.01
The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J (2012) 0.99
AMP-activated protein kinase and metabolic control. Handb Exp Pharmacol (2011) 0.99
Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol (2014) 0.98
Are Metformin Doses Used in Murine Cancer Models Clinically Relevant? Cell Metab (2016) 0.95
Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients. Ann Oncol (2013) 0.95
Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. Int J Breast Cancer (2013) 0.94
Metformin Pharmacokinetics in Mouse Tumors: Implications for Human Therapy. Cell Metab (2016) 0.90
Effect of different doses of metformin on serum testosterone and insulin in non-diabetic women with breast cancer: a randomized study. Clin Breast Cancer (2012) 0.87
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. J Clin Oncol (2016) 0.85
MicroRNAs: Non-coding fine tuners of receptor tyrosine kinase signalling in cancer. Semin Cell Dev Biol (2016) 0.85
E2F inhibition synergizes with paclitaxel in lung cancer cell lines. PLoS One (2014) 0.83
Diagnostic and prognostic value of microRNA-21 in colorectal cancer: an original study and individual participant data meta-analysis. Cancer Epidemiol Biomarkers Prev (2014) 0.83
Histone acetylation, chromatin remodelling and nucleotide excision repair: hint from the study on MFA2 in Saccharomyces cerevisiae. Cell Cycle (2005) 0.83
The metabolic switch and its regulation in cancer cells. Sci China Life Sci (2010) 0.81
MicroRNA-21 promotes cell proliferation, migration, and resistance to apoptosis through PTEN/PI3K/AKT signaling pathway in esophageal cancer. Tumour Biol (2016) 0.80
mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Oncotarget (2015) 0.78
Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells. Oncol Res (2015) 0.78
Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells. Anticancer Res (2010) 0.78
MicroRNA-497 inhibits the proliferation, migration and invasion of human bladder transitional cell carcinoma cells by targeting E2F3. Oncol Rep (2016) 0.77
Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat Med (2014) 3.13
Epigenetic silencing of miR-145-5p contributes to brain metastasis. Oncotarget (2015) 0.88
Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging. Aging Cell (2015) 0.83
Metformin decreases circulating androgen and estrogen levels in nondiabetic women with breast cancer. Clin Breast Cancer (2013) 0.80
Salsalate (Salicylate) Uncouples Mitochondria, Improves Glucose Homeostasis, and Reduces Liver Lipids Independent of AMPK-β1. Diabetes (2016) 0.80
Adherence to WCRF/AICR cancer prevention recommendations and metabolic syndrome in breast cancer patients. Int J Cancer (2015) 0.78
Skeletal muscle AMPK is essential for the maintenance of FNDC5 expression. Physiol Rep (2015) 0.78
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels. Diabetes (2016) 0.78
MicroRNAs: short non-coding players in cancer chemoresistance. Mol Cell Ther (2014) 0.78
Cynara scolymus affects malignant pleural mesothelioma by promoting apoptosis and restraining invasion. Oncotarget (2015) 0.76
Skeletal muscle ACC2 S212 phosphorylation is not required for the control of fatty acid oxidation during exercise. Physiol Rep (2015) 0.75
MiR-204 down-regulation elicited perturbation of a gene target signature common to human cholangiocarcinoma and gastric cancer. Oncotarget (2017) 0.75
Altered peritumoral microRNA expression predicts head and neck cancer patients with a high risk of recurrence. Mod Pathol (2017) 0.75